Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ac-225-labeled anti-HER2 antibody
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
Ac-225-labeled anti-HER2 antibody refers to a class of targeted alpha-radiopharmaceutical therapies (α-RPT) consisting of an antibody or antibody fragment targeting human epidermal growth factor receptor 2 (HER2) conjugated to the alpha-emitting radioisotope actinium-225 (Ac-225). This therapeutic platform is designed to selectively deliver highly cytotoxic alpha radiation to HER2-overexpressing cancer cells, such as those in breast, ovarian, and gastric cancers. Upon binding to HER2 on the cell surface, the radioconjugate is internalized, and the decay of Ac-225 releases high-energy alpha particles that induce lethal DNA double-strand breaks in the target cells while sparing surrounding healthy tissues due to the short path length of alpha radiation.
- Other names
- 225Ac-labeled anti-HER2 antibodyactinium-225-labeled anti-HER2 antibodyactinium225-labeled anti-HER2 antibodyactinium 225-labeled anti-HER2 antibody
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Ac-225-labeled anti-HER2 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ac-225-labeled anti-HER2 antibody.